These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 16616235)

  • 1. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease.
    Musicant SE; Taylor LM; Peters D; Schuff RA; Urankar R; Landry GJ; Moneta GL
    J Vasc Surg; 2006 Apr; 43(4):772-80; discussion 780. PubMed ID: 16616235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease.
    Nicoloff AD; Taylor LM; Sexton GJ; Schuff RA; Edwards JM; Yeager RA; Landry GJ; Moneta GL; Porter JM;
    J Vasc Surg; 2002 Jan; 35(1):38-46; discussion 46-7. PubMed ID: 11802131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events.
    Vainas T; Stassen FR; de Graaf R; Twiss EL; Herngreen SB; Welten RJ; van den Akker LH; van Dieijen-Visser MP; Bruggeman CA; Kitslaar PJ
    J Vasc Surg; 2005 Aug; 42(2):243-51. PubMed ID: 16102622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease.
    McDermott MM; Greenland P; Green D; Guralnik JM; Criqui MH; Liu K; Chan C; Pearce WH; Taylor L; Ridker PM; Schneider JR; Martin G; Rifai N; Quann M; Fornage M
    Circulation; 2003 Jul; 107(25):3191-8. PubMed ID: 12810614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
    Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
    J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study.
    Tzoulaki I; Murray GD; Lee AJ; Rumley A; Lowe GD; Fowkes FG
    Eur Heart J; 2007 Feb; 28(3):354-62. PubMed ID: 17213229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
    Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
    Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
    Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
    J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk.
    Pradhan AD; Shrivastava S; Cook NR; Rifai N; Creager MA; Ridker PM
    Circulation; 2008 Feb; 117(6):823-31. PubMed ID: 18227386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.
    Tzoulaki I; Murray GD; Lee AJ; Rumley A; Lowe GD; Fowkes FG
    Circulation; 2005 Aug; 112(7):976-83. PubMed ID: 16087797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein predicts future arterial and cardiovascular events in patients with symptomatic peripheral arterial disease.
    Hogh AL; Joensen J; Lindholt JS; Jacobsen MR; Ostergaard L
    Vasc Endovascular Surg; 2008; 42(4):341-7. PubMed ID: 18458051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis by C-reactive protein and matrix metalloproteinase-9 levels in stable coronary heart disease during 15 years of follow-up.
    Eldrup N; Kragelund C; Steffensen R; Nordestgaard BG
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):677-83. PubMed ID: 21194909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-dimer, magnetic resonance imaging diffusion-weighted imaging, and ABCD2 score for transient ischemic attack risk stratification.
    Cucchiara BL; Messe SR; Sansing L; MacKenzie L; Taylor RA; Pacelli J; Shah Q; Pollak ES; Kasner SE
    J Stroke Cerebrovasc Dis; 2009; 18(5):367-73. PubMed ID: 19717021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease.
    Unlü Y; Karapolat S; Karaca Y; Kiziltunç A
    Thromb Res; 2006; 117(4):357-64. PubMed ID: 15890391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study.
    Smith FB; Lee AJ; Hau CM; Rumley A; Lowe GD; Fowkes FG
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):43-50. PubMed ID: 10691098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death).
    Beckman JA; Preis O; Ridker PM; Gerhard-Herman M
    Am J Cardiol; 2005 Nov; 96(10):1374-8. PubMed ID: 16275181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease.
    Vu JD; Vu JB; Pio JR; Malik S; Franklin SS; Chen RS; Wong ND
    Am J Cardiol; 2005 Sep; 96(5):655-8. PubMed ID: 16125489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.